MedTrace Logo

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

NCT03079531 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-02-05

Study results available
· View outcomes & findings →

Summary

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

Conditions

  • Papulopustular Rosacea

Interventions

DRUG

Secukinumab

Secukinumab 300 mg administered subcutaneously.

Sponsors & Collaborators

  • Anne Chang

    lead OTHER

Principal Investigators

  • Anne Chang, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2019-01-25
Completion
2019-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03079531 on ClinicalTrials.gov